Stratatech is moving forward with tests of a genetically engineered human skin that could heal the sores and wounds many diabetic patients get on their feet.
Madison, WI-based Stratatech, a subsidiary of U.K.-based Mallinckrodt (NYSE: MNK), said Wednesday that it had enrolled the first patient in a study of the skin tissue, called ExpressGraft-C9T1.
Stratatech said the ExpressGraft skin tissue builds on some of the same technologies the company pioneered in developing StrataGraft, its flagship skin replacement product. StrataGraft is cell-based skin tissue designed to coax the bodies of burn patients into regenerating skin … read more